comparemela.com

Latest Breaking News On - E russell mcallister - Page 1 : comparemela.com

BOLD-100 and ATR Inhibitors as a New Avenue for PDAC Targeting at AACR 2024

/PRNewswire/ Bold Therapeutics, a clinical-stage biopharmaceutical company at the forefront of developing innovative metallotherapeutics, has announced that.

San diegoUnited statesSouth koreaBritish columbiaSoult ukpyolsiE russell mcallisterJim pankovichClinical development at bold therapeuticsBold therapeutics incPreclinical development at bold therapeuticsSeoul national university college of medicineBold therapeuticsSeoul national university collegePancreatic ductal adenocarcinomaCellular stress responsesPancreatic ductal

Bold Therapeutics Selected as 2023 Company to Watch by Life Sciences British Columbia

/PRNewswire/ Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel metallotherapeutics, is announcing its selection by Life.

United kingdomBritish columbiaComunidad autonoma de catalunaE russell mcallisterTaiho lonsurfGlenn walthallBayer stivargaMark bazettJim pankovichPreclinical developmentLife sciences british columbiaVancouver convention centreCompany to watch honour rollCompany toLife sciencesBold therapeutics inc

Bold Therapeutics Presents Positive Interim Phase 2 Results for BOLD-100 in Advanced Gastric and Biliary Tract Cancer at ASCO 2023

/PRNewswire/ Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced positive interim.

South koreaUnited statesBritish columbiaE russell mcallisterJim pankovichAmerican society of clinical oncologyClinical developmentBold therapeutics incClinical oncologyPre treated advanced gastricBiliary tract cancerSafety analysisBold therapeuticsBold therapeutics inc

Bold Therapeutics to Present Positive Interim Gastric and Biliary Tract Cancer Results at ASCO 2023 Annual Meeting

/PRNewswire/ Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, will be presenting positive.

British columbiaUnited statesTaiho lonsurfBayer stivargaE russell mcallisterBold therapeutics incAmerican society of clinical oncologyAmerican association for cancer researchClinical oncologyAnnual meetingPre treated advanced gastricBiliary tract cancerSafety analysisAmerican associationCancer researchInterim phase

Bold Therapeutics Presents Jaw-Dropping Interim Phase 2 Clinical Data for BOLD-100 in the Treatment of Advanced Colorectal Cancer at AACR 2023

/PRNewswire/ Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced positive interim.

British columbiaSouth koreaUnited statesTaiho lonsurfE russell mcallisterBayer stivargaAmerican society of clinical oncologyAmerican association for cancer researchBold therapeutics incAmerican associationCancer researchCirculating cytokine changes when administeredAdvanced gastrointestinal cancer patientsDose escalation studyPre treated advanced colorectal cancerInterim efficacy

vimarsana © 2020. All Rights Reserved.